Third Pole Therapeutics is a biotechnology company that is developing and commercializing novel, portable inhaled nitric oxide (iNO) delivery systems for the treatment of pulmonary hypertension and other cardio-pulmonary diseases. The company's proprietary technology, known as the iNOvent™ platform, enables on-demand, targeted delivery of iNO to patients in a variety of settings, including hospitals, clinics, and homes. Third Pole Therapeutics aims to improve patient outcomes and quality of life by providing safe, effective, and accessible iNO therapy.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/16/2023 | Series B-1 | $69.4MM | $xx.xx | $200.27MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,110,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.2x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|
||||||
02/16/2023 | Series B-3 | $32MM | $xx.xx | $200.27MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
972,939
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.2x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|
||||||
02/16/2023 | Series B-2 | $34.32MM | $xx.xx | $249.3MM | Acord Campus Taiwan, Starpath Ventures | |
Price per Share
$xx.xx
Shares Outstanding
940,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.2x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Acord Campus Taiwan, Starpath Ventures
|
||||||
02/16/2023 | Series B-4 | $14MM | $xx.xx | $249.3MM | Acord Campus Taiwan, Starpath Ventures | |
Price per Share
$xx.xx
Shares Outstanding
383,456
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.2x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Acord Campus Taiwan, Starpath Ventures
|
||||||
12/18/2015 | Series A | $17.5MM | $xx.xx | $38.89MM | Saturn Partners | |
Price per Share
$xx.xx
Shares Outstanding
875,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Saturn Partners
|